Enzyvant

Enzyvant is a biotechnology company dedicated to developing transformative therapies for rare diseases with significant unmet needs. No matter how small the community or how complex the condition, we are committed to tirelessly advancing and delivering therapies that can provide the greatest benefit to patients with rare diseases and their families. Current treatment approaches target patients with congenital athymia and Farber disease, and we are working to expand our portfolio to address other rare diseases and conditions.